cyrilzakka/clinical-trials huggingface dataset:
Evaluation of Gel and Solution of Chlorhexidine in Disinfection Root Canals of Primary Anterior Teeth.

The process of removing bacteria and their products from the root canals is an essential step that is achieved through the combination of mechanical preparation and irrigation with chemicals. However, mechanical preparation alone can not reduce the microbial formations inside root canals, so at least about 35% of the root canal walls remain without the preparation tools reaching them.

Many irrigants were used to irrigate the root canals, as sodium hypochlorite and chlorhexidine are the most famous. Although most studies have proven the effectiveness of sodium hypochlorite with its different concentrations in accomplishing this task, some of them showed the inability of the irrigant fluid to eliminate Enterococcus faecalis inside the canals. These bacteria are highly resistant, and therefore endodontic treatment fails in the long term.

Bacteria and their products play an essential role in the initiation and persistence of endodontic diseases. Therefore, eliminating them and preventing the return of their effectiveness is the desired goal in any successful endodontic treatment in the short and long term.

Due to the fact that mechanical preparation of the root canal alone is not capable of removing the entire bacterial content, chemical irrigants were considered necessary to reduce the number of bacteria and toxins resulting from them. Until now, there is no irrigant capable of removing the entire bacterial content from the root canal.

Despite the many advantages of sodium hypochlorite, several studies have revealed the toxicity of the solution in high concentrations of it, and it tends to cause tissue irritation when it comes into contact with the apical tissues.

Chlorhexidine has been used for a long time in dentistry due to its antibacterial properties, long period of effect, and relatively low toxicity. This has prompted its use as an irrigant and an intra-canal dressing in endodontic treatment.

Eligibility Criteria:
Inclusion Criteria:

1. Definitely positive or positive ratings of Frank scale.
2. Physiological root resorption no more than the apical third
3. Symptoms or signs of pulpal necrosis with or without radial lesions (swelling - fistua - abnormal movement).
4. At least 2 mm of bone surrounding the permanent bud.
5. Children who have not taken antibiotics in the past 3 months.

Exclusion Criteria:

1. Systematic or mental disorders.
2. Definitely negative or negative ratings of Frankel scale
3. Existence external or internal abnormal absorption.
Efficacy of a Multimodal Brain Health Intervention for Older African Americans

This study tests the feasibility, acceptability, and efficacy of a multimodal intervention (walking, social engagement, and reminiscence), including the use of wearable digital biomarkers, for cognitively healthy and mildly cognitively impaired African Americans aged 65 and older.

Cognitively healthy and mildly cognitively impaired participants engage in up to 8 weeks of baseline data collection and 4-16 weeks of triadic neighborhood walking using a group tablet device to access pre-programmed 1-mile routes. GPS (Global Positioning System)-triggered historical images of local Black culture and history along the route prompt conversational reminiscence about Portland, Oregon's historically Black neighborhoods. Digital biomarker technology (a continuously worn actigraph watch and an unobtrusive under-the-mattress sleep sensor) and weekly online surveys via a study Chromebook assess feasibility, acceptability, efficacy, and health outcomes. Intermittent discussions and check-ins with participants, and observational sessions will be used to elicit participant feedback.

Eligibility Criteria:
Inclusion Criteria for walkers:

1. Self-identified African American,
2. Age \> 65 years old
3. Reside or resided for \>10 years in Portland's historically Black neighborhoods (to be familiar with Memory Markers about this area),
4. Able to ambulate independently.
5. Meeting Cognition Criteria

   1. Participants with MCI (Mild Cognitive Impairment) will meet criteria consistent with the criteria outlined by the NIA-Alzheimer's Association workgroup
   2. Participants without cognitive impairment will have a Montreal Cognitive Assessment (MoCA) score \> 24 (and not meet MCI criteria). Participants' cognitive function should allow them to get to and from walk locations independently or with minimal assistance.
6. Cognitive function allows independent (or minimally assisted) travel to and from walk locations
7. In-home reliable broadband internet (for weekly online surveys).
8. Ability to read, speak, and understand English

Exclusion Criteria:

1. Self-reported or clinically diagnosed dementia
2. Significant disease of the central nervous system
3. Severely depressed (CES-D score \> 16), significantly symptomatic psychiatric disorder
4. Advanced cardiovascular disease that would make walking difficult, including history of congestive heart failure
5. Unstable insulin-dependent diabetes mellitus, received diagnosis Type 1 Diabetes, started insulin within past 3 months, hospitalized for hypoglycemia within past 6 months.
A Study to Evaluate Safety and Efficacy of Oral Febuxostat in Patients With Gout

This is a multicenter, open label, randomized, allopurinol-controlled, parallel-design study. Approximately 120 subjects will be randomly assigned in 1:1 ratio to receive febuxostat, or allopurinol for subjects with gout.


Eligibility Criteria:
Inclusion Criteria:

* Subjects will also have a history or presence of gout as defined by the American College of Rheumatology (ACR) criteria
* Subject has serum urate level \>= 8.0 mg/dL at the screening Visit

Exclusion Criteria:

* Female subject who is breast-feeding or pregnant
* Subject has a history of xanthinuria
* Subject who is intolerant of allopurinol, ie hypersensitivity, Steven-Johnson syndrome/topic epidermal necrolysis
* Subject who takes allopurinol \> 300 mg/day and with serum urate level \> 8mg/dL
* Subject who is HLA B\*5801 positive
* Subject who is receiving thiazide diuretic therapy
* Subject who has secondary hyperuricemia
* Subject who requires concurrent therapy with any systemic or topical medications, prescribed or non-prescribed, containing aspirin or other salicylates (low doses of aspirin will be allowed(ie. =\< 325mg/day)
* Subject who requires therapy with prednisone \> 10 mg/ day during the study
* Subject who has active liver disease or hepatic dysfunction, defined as both ALT and AST \> 1.5 times the upper limit of normal
* Subject who has serum creatinine \>= 1.5mg/dL
* Subject who has any another significant medical condition as defined by the investigator that would interfere with the treatment, safety or compliance with the protocol (eg. A clinically significant ECG result)
* Subject who has a history of cancer (other than basal cell carcinoma of the skin) within 5 years prior to the study, or has taken any systemic cancer chemotherapy within 5 years prior to the study
* Subject who has previously participated in a clinical study in which febuxostat was administered
* Subject who has participated in another investigational trial within the 30 days prior to the study
Anatomical Study of the Arteries of the Skin on Amputation Legs

PRIMARY OBJECTIVE Qualitatively describe the distribution of cutaneous arteries in patients with long-term occlusive arterial disease.

SECONDARY OBJECTIVE To compare the distribution of cutaneous arteries observed on the legs of arteritic patients with that observed on non-arteritic legs (from bodies given to science).

Arterial patient coming to CHRU Nancy, in the Vascular and Endoluminal Surgery Department, to undergo leg amputation.

Usually, after the amputation of the leg in the operating theatre, the surgical waste is destroyed.

Instead of being destroyed, the leg will be used for research.

Eligibility Criteria:
Inclusion Criteria:

* Major Patient
* Patient with late stage occlusive arteriopathy with lower limb amputation
* Patient who did not oppose the search
* Patient affiliated to a social security scheme

Exclusion Criteria:

* Patients with infectious diseases not accessible in the anatomy laboratory
* Woman of childbearing age without effective contraception
* Persons referred to in Articles L. 1121-5 to L. 1121-8 and L1122-2 of the Public Health Code :
* Pregnant woman, parturient or nursing mother
* Person deprived of liberty by a judicial or administrative decision,
* Person under psychiatric care pursuant to Articles L.3212-1 and L.3213-1 of the Public Health Code
* Person admitted to a health or social institution for purposes other than research
* Minor person (not emancipated)
* Adult subject to a legal protection measure (guardianship, trusteeship, protection of justice)
* Major person who is not in a position to express consent and who is not subject to a legal protection measure
COVID-19 Infection and Idiopathic Membranous Nephropathy

Infection is one of common risk factors for relapsing of idiopathic membranous nephropathy (IMN). However, it is still unclear wheather COVID-19 infection can induce the relapsing of IMN. Herein, in this prospective, multi-center, cohort study, the investigator enrolled the IMN patients with COVID-19 infection.

All subjects will be followed for three months with four visits at 1, 2 and 3 months. Then the investigator will compare the rate of replase of IMN in the two groups to evaluate the association of COVID-19 infection and replapse of IMN.


Eligibility Criteria:
Inclusion Criteria:

1. the status of nephrotic syndrome is complete remmision or partial remmision;
2. estimated glomerular filtration rate (eGFR according to the CKD-EPI formula) ≥60 mL/min per 1.73 m2;
3. patients with a moderate risk of IMN.

Exclusion Criteria:

1. secondary causes of MN;
2. the labarotary data two months before enrolement is absent.
Pilot Study of Behavioral Activation for Prolonged Grief

The Institute of Medicine identifies Prolonged Grief (PG) as a critical under-addressed public health problem for which are no empirically supported treatments. The purpose of this application is to pilot-test Behavioral Activation (BA) therapy for PG. BA is a well supported, stand alone intervention for depression and recently applied to posttraumatic stress disorder, which reduces rumination and avoidance behaviors that otherwise thwart access to natural rewarding contingencies and resources. The treatment focuses on promoting stable, active routines, self-care behaviors, enhanced self-efficacy, and reengagement with pleasurable activities and significant social resources. Rumination, disengagement, and low self-efficacy are defining features of PG. Further, in response to loss of intimates, the key factors that differentiate resilient people from those that have difficulties adapting is the maintenance or fast resumption of social and occupational functioning. Thus, the main hypothesis of this study is that BA for PG will result in clinically significant reductions in rumination and functional disengagement. This is a preliminary small-scale pilot assessment of potential efficacy and feasibility of completing a large scale study of BA for PG.


Eligibility Criteria:
Inclusion Criteria:

* meet criteria for Prolonged Grief Disorder
* must be 21 years old or older
* if taking psychotropic medication, must have been on a stable dose for three or more months prior to study entry

Exclusion Criteria:

* presence of active suicidal or homicidal ideation
* a history of psychotic symptoms
* current participation in psychosocial treatment focused on grief symptoms
* active substance abuse
A Study of TQ-B3525 in Subjects With Relapse/Refractory Diffuse Large B-cell Lymphoma （DLBCL）

This is a study to evaluate the efficacy and safety of TQ-B3525 in subjects with relapse/refactory diffuse large B-cell lymphoma who have received at least 2 lines of therapeutic schedules including rituximab. TQ-B3525 tablet administered 20mg orally, once daily in 28-day cycle.


Eligibility Criteria:
Inclusion Criteria:

* 1.Understood and signed an informed consent form; 2. 18 years and older, Eastern Cooperative Oncology Group(ECOG) performance status score of 0 to 2, Life expectancy ≥ 3 months; 3. Relapsed/refractory Diffuse Large B-cell lymphoma （DLBCL); 4. Has received at least two lines of previous treatment, the latest treatment confirmed no objective response, or disease progress after treatment, either of the treatment should conclude rituximab; 5. Has at least one measurable lesion; 6. Adequate organ system function; 7. Male or female subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 6 months after the last dose of study (such as intrauterine devices , contraceptives or condoms) ；No pregnant or breastfeeding women, and a negative pregnancy test are received within 7 days before the first administration.

Exclusion Criteria:

* 1. DLBCL transformed from previously diagnosed indolent lymphoma; 2. Has central nervous system violation; 3. Has received other PI3K inhibitors or CAR-T treatments; 4. Has diagnosed and/or treated additional malignancy within 3 years prior to the first administration; 5. Has type I diabetes or uncontrolled type II diabetes; 6.Has history of interstitial lung disease; 7. Has a history of immunodeficiency diseases; 8. Has multiple factors affecting oral medication; 9.Has adverse events caused by previous therapy except alopecia that did not recover to ≤grade 1; 10. Has received systemic steroid treatment within 7 days before the first administration; 11. Has received other systemic anti-tumor medications within 4 weeks before the first administration, or still within the 5 half-life of the medication, which occurs first; 12. Has active infections within 4 weeks before the first administration; 13. Has received surgery, or unhealed wounds within 4 weeks before the first administration; 14. Has a history of autologous hematopoietic stem cell transplant within 3 months; 15. Has a history of allogeneic hematopoietic stem cell transplant; 16. Grade II or higher cardiovascular disease within 6 months before the first administration; 17. QTCF \> 480ms, LVEF \< 50%; 18. Urinary protein ≥ 2 +, and 24-hour urinary protein quantity\>1g within 7 days; 19. Has active hepatitis B or C; 20. Has psychotropic substances abuse or a mental disorder; 21. Has other conditions that make it inappropriate for the patient to be enrolled based on investigator's opinion.
Surgery Versus No Surgery for Osteoarthritis (OA) of the Knee

The purpose of this study is to discover whether arthroscopic surgery is helpful in controlling the symptoms of osteoarthritis of the knee.

Although arthroscopic surgery has been widely used for osteoarthritis of the knee, scientific evidence to support its efficacy is lacking. This study will compare optimized physical and medical therapy alone with arthroscopic treatment in addition to optimized physical and medical therapy.

Eligibility Criteria:
Inclusion Criteria:

* Idiopathic or secondary osteoarthritis of the knee with Grade II to IV radiographic severity as defined by the modified Kellgren and Lawrence classification

Exclusion Criteria:

* Patients with inflammatory or post-infectious arthritis
* Those who had undergone previous arthroscopic treatment for knee osteoarthritis
* Those with isolate Grade III to IV medical compartment osteoarthritis with greater than 5 degrees of varus deformity.
Evaluation of the Benefit and Safety of Localized Tissue Hydration in the Management of Chronic Low Back Pain

The purpose of this study is to evaluate the benefit of Localized Tissue Hydration associated with standard management of chronic common low back pain, in terms of improvement in the numerical verbal scale score at 6 months.

This is a proof-of-concept, single-center, prospective, interventional, non-randomized Phase II study designed to evaluate the benefit of 0.9% sodium chloride Localized Tissue Hydration in patients with chronic common low back pain.

The study corresponds to a clinical trial of a medicinal product in compliance with Regulation (EU) n°536/2014.

The study population is composed of patients suffering from chronic common low back pain for more than 3 months with a numerical verbal scale ≥ 5.

Patients will receive a localized subcutaneous injection of 0.9% sodium chloride over 10 sessions (1 session per week), combined with standard management including stage I and II analgesics and physiotherapy in accordance with the recommendations of the French National Authority for Health.

Eligibility Criteria:
Inclusion Criteria:

* Patient 18 years of age or older ;
* Patient with chronic, non-operated low-back pain operated for more than 3 months (verbal numerical scale ≥ 5);
* Chronic common lumbago not requiring surgical management surgical ;
* Lumbar MRI performed as part of routine care and available available for the inclusion visit;
* For women of childbearing age, use of a highly effective contraceptive method;
* Patient affiliated to a French health insurance scheme;
* Patient has signed an informed consent form.

Exclusion Criteria:

* Pregnant or breast-feeding woman;
* Patient in accident at work ;
* Patient with radicular syndrome;
* Contraindication to magnetic resonance imaging or CT scan;
* Severe cases of hydric inflation and hydrosodic retention, particularly in cases of :

  * Decompensated heart failure;
  * Acute renal failure with oliguria or anuria;
  * Decompensated liver failure;
  * Pre-eclampsia/eclampsia.
* Hypochloremia ;
* Hypernatremia ;
* Patients of legal age subject to legal protection, guardianship, curatorship or deprived of liberty by judicial or administrative decision;
* Patient hospitalized without consent;
* Patient unable to answer a questionnaire;
* Patients who do not understand or speak French.

Exclusion period for inclusion in another study :

Included patients will not be allowed to participate in another interventional study during the entire follow-up period. The exclusion period is 8.5 months.
Optimal Endotracheal Cuff Pressure During Hospitalization in Intensive Care Units Using AnapnoGuard 100 System

Hospitech Respiration Ltd has developed the AnapnoGuard system, an innovative system intended to enhance optimal endotracheal tube (ETT) cuff inflation, by monitoring carbon dioxide (CO2) in upper airways of mechanically ventilated patients. Optimal ETT cuff inflation will lead to a reduction of complication rate related to mechanical ventilation procedure.

This study was design in order to evaluate the feasibility of using the AnapnoGuard system.


Eligibility Criteria:
Inclusion Criteria:

* Age above 18 (men and woman);
* Patient is admitted to ICU and expected to receive mechanical ventilation for at least 48 hours;
* Normal chest X-ray;
* Connection of the ETT to the AnapnoGuard system less than 6 hours from intubation initiation;
* Signed informed consent by subject's legally acceptable representative.

Exclusion Criteria:

* Patients who had been treated with mechanical ventilation during the last year;
* Fever from known chest/lung origin;
* Patients with facial, oropharyngeal or neck trauma;
* BMI\>35;
* Height \< 1.6 m;
* Any chest X-ray pathology during the first 24 hours post intubation;
* More than 7 days hospitalization prior to the intubation. Chest/lung infection.
Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer

The purpose of this two-stage phase II study is to assess the efficacy of BKM120, as measured by determining the progression free survival (PFS), in patients with pretreated metastatic Non-small Cell Lung Cancer (NSCLC) that exhibits PI3K pathway activation. BKM120 will be investigated in two groups of NSCLC patients according to the histology of the cancer: squamous and non-squamous.


Eligibility Criteria:
Inclusion Criteria:

* Histologically confirmed NSCLC with activated PI3K pathway
* Progressive disease after prior systemic antineoplastic treatment(s) for advanced NSCLC
* Archival or fresh tumor biopsy must be available for profiling
* Measurable and/or non-measurable disease as per RECIST 1.1 criteria
* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
* Adequate organ function as assessed by laboratory tests

Exclusion Criteria:

* Patient has received previous treatment with PI3K inhibitors
* Patient with squamous NSCLC has received more than one line of chemotherapy treatment for metastatic disease; patient with non-squamous NSCLC has received more than two lines of systemic antineoplastic treatment for metastatic disease
* Uncontrolled or symptomatic CNS metastases
* Concurrent use of any other approved or investigational antineoplastic agent
* Radiotherapy ≤ 28 days prior to starting study drug
* Major surgery within 28 days prior to starting study drug
* History of clinically significant cardiac dysfunction, mood disorders, or poorly controlled diabetes mellitus
* Current treatment with medication that has a known risk to prolong the QT interval or inducing Torsades de Pointes
* Impairment of gastrointestinal (GI) function
* Chronic treatment with steroids or another immunosuppressive agent.
* Concurrent severe and/or uncontrolled medical condition
* Currently receiving Warfarin or another coumarin derivative
* Known history of HIV infection
* Sensory neuropathy with functional impairment (CTC grade 2 neuropathy, regardless of causality)
* Pregnancy, lactation, or breastfeeding
* Woman of child-bearing potential

Other protocol-defined inclusion/exclusion criteria may apply
Social Media and COVID-19

In this protocol, we seek to examine the role of popular messaging platform WhatsApp in information spread during a crisis. As there have been few global crises in the last decade (coinciding with the rise of social media), the role of private messaging platforms such as WhatsApp during crisis contexts remains understudied. During the current COVID-19 global health crisis, we undertook this study to: (1) characterize the nature of WhatsApp use during crises, (2) characterize the profiles of WhatsApp users (3) understand how WhatsApp usage links to well-being (fear and thoughts about COVID-19).


Eligibility Criteria:
Inclusion Criteria:

* At least 21 years
* Has stayed in Singapore for at least 2 years
* Has a WhatsApp account that can be used for the research study

Exclusion Criteria:

* Below 21 years
* Has stayed in Singapore for less than 2 years
* Does not have a WhatsApp account that can be used for the research study